eNOS3 Genetic Polymorphism Is Related to Post-Ablation Early Recurrence of Atrial Fibrillation.
10.3349/ymj.2015.56.5.1244
- Author:
Jaemin SHIM
1
;
Jae Hyung PARK
;
Ji Young LEE
;
Jae Sun UHM
;
Boyoung JOUNG
;
Moon Hyoung LEE
;
Patrick T ELLINOR
;
Hui Nam PAK
Author Information
1. Department of Cardiology, Korea University Anam Hospital, Seoul, Korea.
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords:
Atrial fibrillation;
eNOS gene;
catheter ablation;
recurrence
- MeSH:
Aged;
Alleles;
Atrial Fibrillation/genetics/*surgery;
Case-Control Studies;
*Catheter Ablation;
Coronary Artery Disease;
Female;
Follow-Up Studies;
Genotype;
Humans;
Logistic Models;
Male;
Middle Aged;
Nitric Oxide Synthase Type III/*genetics;
Polymorphism, Single Nucleotide/*genetics;
Recurrence;
Republic of Korea;
Stroke/genetics
- From:Yonsei Medical Journal
2015;56(5):1244-1250
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Previous studies have demonstrated an association between eNOS polymorphisms and atrial fibrillation (AF). We sought to determine whether eNOS polymorphisms are associated with AF recurrence after a radiofrequency catheter ablation (RFCA). MATERIALS AND METHODS: A total of 500 consecutive patients (56+/-11 years, 77% male) with paroxysmal (68%) or persistent (32%) AF who underwent RFCA and 500 age, gender-matched controls were genotyped for the eNOS3 single nucleotide polymorphism (rs1799983). AF recurrence was monitored according to 2012 ACC/AHA/ESC guidelines. RESULTS: The frequencies of the rs1799983 variant alleles (T) in the case and control group were not significantly different (OR 1.05, 95% CI 0.75-1.46, p=0.798). AF patients with rs1799983 variants were more likely to have coronary artery disease or stroke than those without genetic variant at this gene (31.0% vs. 17.3%, p=0.004). During mean 17 months follow-up, early recurrence of AF (ERAF; within 3 months) and clinical recurrence (CR) of AF were 31.8% and 24.8%, respectively. The rs1799983 variant was associated with higher risk of ERAF (OR 1.71, 95% CI 1.06-2.79, p=0.028), but not with CR. ERAF occurred earlier (11+/-16 days) in variant group than those without variant allele (20+/-25 days, p=0.016). A multiple logistic regression analysis showed that presence of the rs1799983 variant (OR 1.75, 95% CI 1.07-2.86, p=0.026) and persistent AF were independent predictors for ERAF after AF ablation. CONCLUSION: The rs1799983 variant of the eNOS3 gene was associated with ERAF, but not with CR, after RFCA. eNOS3 gene variants may have a potential role for stratification of post-ablation management.
